Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : Close to a key resistance level

01/20/2021 | 02:52am EDT
long trade
Target price hit
Entry price : 112.65$ | Target : 125$ | Stop-loss : 104.5$ | Potential : 10.96%
Abbott Laboratories shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern.
Investors have an opportunity to buy the stock and target the $ 125.
Abbott Laboratories : Abbott Laboratories : Close to a key resistance level
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The company returns high margins, thereby supporting business profitability.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 88.71 USD

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at USD 114.42.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • With an enterprise value anticipated at 6.05 times the sales for the current fiscal year, the company turns out to be overvalued.
  • With a 2020 P/E ratio at 45.97 times the estimated earnings, the company operates at rather significant levels of earnings multiples.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 39 766 M - -
Net income 2021 5 967 M - -
Net Debt 2021 8 719 M - -
P/E ratio 2021 35,7x
Yield 2021 1,43%
Capitalization 213 B 213 B -
EV / Sales 2021 5,57x
EV / Sales 2022 5,53x
Nbr of Employees 109 000
Free-Float 89,0%
Upcoming event on ABBOTT LABORATORIES
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 119,81 $
Average target price 128,81 $
Spread / Average Target 7,51%
EPS Revisions
Managers and Directors
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES9.43%212 881
MEDTRONIC PLC11.17%172 114
BECTON, DICKINSON AND COMPANY1.79%72 539
HOYA CORPORATION5.22%50 566
ALIGN TECHNOLOGY, INC.17.05%50 298
SARTORIUS STEDIM BIOTECH59.10%49 743